COVID-19 Impact on Global Urological Cancer Therapeutics Drugs, Market Insights and Forecast to 2026

COVID-19 Impact on Global Urological Cancer Therapeutics Drugs, Market Insights and Forecast to 2026

  • QYResearch
  • June 2020
  • Pharmaceutical
  • 152 pages

Report Description

1
1
Urological Cancer Therapeutics Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Urological Cancer Therapeutics Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.

Segment by Type, the Urological Cancer Therapeutics Drugs market is segmented into
Xofigo (radium Ra 223 dichloride)
Jevtana (cabazitaxel)
Inlyta (axitinib)
Votrient (pazopanib hydrochloride)
Sutent (sunitinib malate)
Zytiga (abiraterone acetate)
Xtandi (enzalutamide)
Opdivo (nivolumab)
Provenge (sipuleucel-T)

Segment by Application, the Urological Cancer Therapeutics Drugs market is segmented into
Hospital
Medical Research Laboratory
Others

Regional and Country-level Analysis
The Urological Cancer Therapeutics Drugs market is analysed and market size information is provided by regions (countries).
The key regions covered in the Urological Cancer Therapeutics Drugs market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Urological Cancer Therapeutics Drugs Market Share Analysis
Urological Cancer Therapeutics Drugs market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Urological Cancer Therapeutics Drugs business, the date to enter into the Urological Cancer Therapeutics Drugs market, Urological Cancer Therapeutics Drugs product introduction, recent developments, etc.
The major vendors covered:
Novartis
Pfizer
Johnson & Johnson
AstraZeneca
Astellas
Bristol-Myers Squibb
Abbott Laboratories
Celgene Corporation
Dendreon Corporation
Ferring Pharmaceuticals
GlaxoSmithKline plc
Indevus Pharmaceuticals Inc
Ipsen
Roche Healthcare
Sanofi S.A.

Have query on this report?

Make an Enquiry
1 Study Coverage
1.1 Urological Cancer Therapeutics Drugs Product Introduction
1.2 Market Segments
1.3 Key Urological Cancer Therapeutics Drugs Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
List of Tables
Table 1. Urological Cancer Therapeutics Drugs Market Segments
Table 2. Ranking of Global Top Urological Cancer Therapeutics Drugs Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Urological Cancer Therapeutics Drugs Market Size Growth Rate by Type 2020-2026 (K MT) & (US$ Million)
Table 4. Major Manufacturers of Xofigo (radium Ra 223 dichloride)
Table 5. Major Manufacturers of Jevtana (cabazitaxel)

Success Stories

Our Clients

Tell Us What You Need and We’ll Get Back with the Best Solutions Available.

*
*
*

get in touch

Location :

State Tower, 90 State Street, Suite 700, Albany NY - 12207, United States

Call Us :

US/Canada toll free : 866-997-4948

Tel : +1-518-621-2074